Defining an embryonal rhabdomyosarcoma endotype.


Journal

Cold Spring Harbor molecular case studies
ISSN: 2373-2873
Titre abrégé: Cold Spring Harb Mol Case Stud
Pays: United States
ID NLM: 101660017

Informations de publication

Date de publication:
04 2020
Historique:
received: 10 12 2019
accepted: 13 02 2020
entrez: 3 4 2020
pubmed: 3 4 2020
medline: 28 5 2021
Statut: epublish

Résumé

Rhabdomyosarcoma (RMS) is the most common childhood soft-tissue sarcoma. The largest subtype of RMS is embryonal rhabdomyosarcoma (ERMS) and accounts for 53% of all RMS. ERMS typically occurs in the head and neck region, bladder, or reproductive organs and portends a promising prognosis when localized; however, when metastatic the 5-yr overall survival rate is ∼43%. The genomic landscape of ERMS demonstrates a range of putative driver mutations, and thus the recognition of the pathological mechanisms driving tumor maintenance should be critical for identifying effective targeted treatments at the level of the individual patients. Here, we report genomic, phenotypic, and bioinformatic analyses for a case of a 3-yr-old male who presented with bladder ERMS. Additionally, we use an unsupervised agglomerative clustering analysis of RNA and whole-exome sequencing data across ERMS and undifferentiated pleomorphic sarcoma (UPS) tumor samples to determine several major endotypes inferring potential targeted treatments for a spectrum of pediatric ERMS patient cases.

Identifiants

pubmed: 32238403
pii: mcs.a005066
doi: 10.1101/mcs.a005066
pmc: PMC7133750
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Biomarkers, Tumor 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2020 Ricker et al.; Published by Cold Spring Harbor Laboratory Press.

Références

Haematologica. 2017 Nov;102(11):1923-1930
pubmed: 28860342
Nat Genet. 2004 Nov;36(11):1159-61
pubmed: 15475955
Br J Cancer. 2017 Jun 6;116(12):1621-1626
pubmed: 28524158
Science. 2009 Aug 21;325(5943):965
pubmed: 19556464
Pediatr Blood Cancer. 2012 Sep;59(3):558-60
pubmed: 22180160
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Cancer Discov. 2014 Feb;4(2):216-31
pubmed: 24436047
Virchows Arch. 2006 Nov;449(5):554-60
pubmed: 17013628
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Clin Oncol. 2003 Jan 1;21(1):78-84
pubmed: 12506174
Mod Pathol. 2014 Sep;27(9):1267-80
pubmed: 24481001
J Clin Invest. 1995 Apr;95(4):1606-11
pubmed: 7706467
Mod Pathol. 2019 Jan;32(1):27-36
pubmed: 30181563
Onco Targets Ther. 2016 Apr 15;9:2211-20
pubmed: 27143916
Oncotarget. 2016 Nov 29;7(48):78255-78268
pubmed: 27825141
Radiol Oncol. 2016 Jul 19;50(3):297-307
pubmed: 27679546
Cell Rep. 2018 Nov 6;25(6):1446-1457
pubmed: 30404001
Nat Genet. 2017 Jul;49(7):1148-1151
pubmed: 28553959
Pathologe. 2010 Mar;31(2):91-6
pubmed: 19997735
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Pediatr Blood Cancer. 2012 Jul 15;59(1):5-10
pubmed: 22378628
Am J Pathol. 2010 Oct;177(4):2080-90
pubmed: 20884963
Nat Genet. 2011 Jun;43(6):527-9
pubmed: 21552266
Cancer Res. 1989 Nov 15;49(22):6324-7
pubmed: 2680062
Genes Chromosomes Cancer. 2016 Nov;55(11):855-63
pubmed: 27239782
Pediatr Blood Cancer. 2017 Dec;64(12):
pubmed: 28521080
Cancer. 2015 Apr 1;121(7):1056-63
pubmed: 25411085
Med Pediatr Oncol. 2000 Aug;35(2):96-103
pubmed: 10918230
J Clin Oncol. 2001 Jun 15;19(12):3091-102
pubmed: 11408506
J Pediatr Hematol Oncol. 2004 Apr;26(4):243-7
pubmed: 15087952
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Cancer Res. 2012 Nov 15;72(22):5889-99
pubmed: 23002205
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Nat Genet. 2014 Jun;46(6):595-600
pubmed: 24793135
J Mol Diagn. 2006 May;8(2):202-8
pubmed: 16645206
Nat Genet. 2010 Aug;42(8):715-21
pubmed: 20601955
Clin Cancer Res. 2012 Feb 1;18(3):748-57
pubmed: 22142829
Biosci Rep. 2019 Feb 5;39(2):
pubmed: 29769411
Curr Protoc Bioinformatics. 2013;43:11.10.1-11.10.33
pubmed: 25431634
Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5
pubmed: 24234437
Asian Pac J Cancer Prev. 2016;17(S3):317-21
pubmed: 27165245
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Cancer Invest. 2000;18(3):223-41
pubmed: 10754991
Int J Clin Exp Pathol. 2015 Apr 01;8(4):3794-802
pubmed: 26097561
Int J Clin Exp Pathol. 2015 Jul 01;8(7):8563-7
pubmed: 26339434
N Engl J Med. 2010 Dec 30;363(27):2628-37
pubmed: 21190457
Virchows Arch. 2000 Apr;436(4):305-11
pubmed: 10834531

Auteurs

Cora A Ricker (CA)

Children's Cancer Therapy Development Institute, Beaverton, Oregon 97005, USA.

Kenneth Crawford (K)

Children's Cancer Therapy Development Institute, Beaverton, Oregon 97005, USA.

Kevin Matlock (K)

Omics Data Automation, Beaverton, Oregon 97221, USA.

Melvin Lathara (M)

Omics Data Automation, Beaverton, Oregon 97221, USA.

Bernard Seguin (B)

Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado 80525, USA.

Erin R Rudzinski (ER)

Seattle Children's Hospital, Seattle, Washington 98105, USA.

Noah E Berlow (NE)

Children's Cancer Therapy Development Institute, Beaverton, Oregon 97005, USA.

Charles Keller (C)

Children's Cancer Therapy Development Institute, Beaverton, Oregon 97005, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH